{"entity":{"id":"nct04550260","kind":"trial","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","aka":["KUNLUN"],"tldr":"A phase 3 trial of Durvalumab, Cisplatin and Capecitabine in oesophageal cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC is a phase 3 interventional study registered as NCT04550260 by AstraZeneca, with 640 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2027-06-30. Interventions recorded: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine and Radiation.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04550260","url":"https://clinicaltrials.gov/study/NCT04550260"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal","oesophageal-squamous-cell-carcinoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab","cisplatin","capecitabine"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04550260","phase":"3","setting":"A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)","sponsor":"AstraZeneca","started":"2020-10-19","startedType":"actual","enrolled":640,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04550260/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}